On Thursday, Berenberg renewed its buy recommendation on GSK shares, with a target price of 1,820 pence.

In a research note, the analyst explains that he expects investor attention to shift from the Zantac dossier and the latest cancer clinical results to Arexvy, the company's new RSV vaccine.

While GSK is due to present new data to an FDA advisory committee next week, the stock could well benefit from good news relating to an expansion of the indication to protect a younger and more vulnerable population, and not just the elderly, he points out in the study.

While he acknowledges that the Zantac dossier remains a risk factor, the intermediary believes that this element is now well integrated into the stock market valuation.

Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.